PDCD1 and neoplasm: This understanding led to the development of inhibitory immune checkpoint-blocking antibodies, such as anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-LAG-3, and anti-TIM-3, which reverse inhibitory signals and enhance tumor-specific Tc cell proliferation [175, 176].